Clinical Trial: A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07060807) titled 'A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)' on July 02.

Brief Summary: Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic.

* HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread

* HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2

* Unresectable locally advanced means the cancer cannot be completel...